When Will Medicare Cover GLP-1 Drugs Like Ozempic or Wegovy?

The useful distinction is this: drug approval is what a medication is allowed to treat; plan coverage is whether, and under what rules, a particular Part D plan will pay for it. Those are related decisions, but they are not the same decision. Treating a GLP-1 prescription as a single category is where coverage questions become needlessly confusing.

Will Medicare pay for Ozempic if I have type 2 diabetes?

Medicare Part D can cover a GLP-1 drug for type 2 diabetes, subject to the beneficiary's specific plan formulary and coverage rules. The Centers for Medicare & Medicaid Services states that type 2 diabetes is an indication eligible for Part D coverage, so a beneficiary with that diagnosis should obtain the medication through the Part D plan rather than through the Medicare GLP-1 Bridge.

DailyMed's Ozempic prescribing information describes Ozempic as a GLP-1 receptor agonist used with diet and exercise to improve glycemic control in adults with type 2 diabetes. The label also includes risk-reduction uses for certain adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. It does not list weight reduction as an indication.

That label difference matters. A plan may evaluate an Ozempic claim as treatment for diabetes and apply its diabetes-related formulary rules. It may also require prior authorization, which Medicare.gov defines as plan approval based on its own requirements before coverage begins. The prescriber may need to show medical necessity and document that the plan's criteria are met.

Does Medicare cover Wegovy for weight loss?

Medicare may cover Wegovy for weight management through the temporary Medicare GLP-1 Bridge for qualifying beneficiaries, but the Bridge is not the Part D benefit and it does not make every weight-loss prescription covered. CMS says the demonstration runs from July 1, 2026, through December 31, 2027, outside the Part D coverage and payment flow.

CMS identifies Wegovy and Zepbound KwikPen among products currently eligible through the Bridge when prescribed to reduce excess body weight and maintain weight reduction. For Bridge access, a prescriber must submit prior authorization and attest that clinical criteria are met. According to CMS's 2026 provider guidance, the criteria include a body mass index of at least 35, a body mass index of at least 30 with specified conditions, or a body mass index of at least 27 with prediabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease.

DailyMed's Wegovy prescribing information distinguishes weight management from other approved uses. It indicates Wegovy with a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity and in adults with overweight plus at least one weight-related comorbidity. The label also includes cardiovascular-risk reduction for adults with established cardiovascular disease and obesity or overweight, so the purpose documented for the prescription is not a paperwork detail. It is part of the coverage question.

Why does my Medicare Part D plan cover one GLP-1 drug but not another?

A Part D plan can cover one GLP-1 drug but not another because its formulary, diagnosis-specific rules, prior authorization criteria, and step-therapy requirements differ by product. A formulary is the plan's drug list. Prior authorization is the rule requiring approval before coverage. Step therapy is a type of prior authorization that requires trying a less-expensive effective formulary drug before moving to a more-expensive option, according to Medicare.gov's Drug Plan Rules.

The comparison is not Ozempic versus Wegovy in the abstract. It is a four-part check: the drug, the FDA-approved use documented by the prescriber, the plan's formulary entry, and the plan's utilization-management rules. Medicare.gov specifically notes that plans may use prior authorization when a drug is covered for one medical condition but not another. That is why two claims for the same medication can produce different coverage results without either result being arbitrary.

1. Locate the plan's current formulary and search for the exact medication name.
2. Read the drug's notes for prior authorization, step therapy, quantity limits, and covered-use restrictions.
3. Ask the plan whether the documented diagnosis meets its coverage rule before assuming a pharmacy rejection is final.
4. Request a coverage determination or an exception when the rule does not fit the documented medical situation.

For budget planning, do not compare only whether a medication appears on a formulary. Compare the plan rule, the pharmacy used, and the route of coverage. Medicare Plan Compare allows beneficiaries to enter a ZIP code and save prescriptions and pharmacies to compare plan costs. That creates a repeatable annual review system instead of relying on last year's drug list.

Can Medicare cover a GLP-1 medication for heart disease or sleep apnea?

Medicare can cover a GLP-1 medication for moderate-to-severe obstructive sleep apnea through Part D when the plan's rules are met, and CMS says prescriptions intended to reduce major adverse cardiovascular events should be routed to the beneficiary's Part D plan rather than the Bridge. The route is diagnosis-driven: the Bridge is for eligible weight-management access, while covered Part D indications belong with the Part D plan.

Wegovy's FDA label includes reducing cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight. In the 2024 prescribing information, the cardiovascular-outcomes trial enrolled 17,604 participants age 45 or older with established cardiovascular disease and a body mass index of at least 27; the composite endpoint occurred in 6.5% of Wegovy participants and 8.0% of placebo participants. Those figures explain why cardiovascular risk reduction and weight management cannot be treated as interchangeable reasons for a prescription.

CMS also identifies noncirrhotic MASH as a Part D-eligible indication. Whether a given plan covers a particular GLP-1 for a particular diagnosis still requires checking that plan's formulary and utilization-management terms. Public information provided here does not establish a universal Part D drug list or a universal approval outcome.

Cost-control work is not the same as choosing a medication. The practical system is to verify the diagnosis and drug label with the prescriber, verify the plan rule with the plan, and retain the denial notice if one arrives. Manufacturer-assistance eligibility and cash prices are not established by the sources used for this guide, so they should not be assumed as substitutes for a Part D coverage decision. For related food-budget planning that may support a reduced-calorie eating pattern, see How Can You Meal Prep Healthy High-Protein Meals for the Workweek?.